NEO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NEO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NeoGenomics's change in receivables for the quarter that ended in Mar. 2024 was $-9.1 Mil. It means NeoGenomics's Accounts Receivable increased by $9.1 Mil from Dec. 2023 to Mar. 2024 .
NeoGenomics's change in receivables for the fiscal year that ended in Dec. 2023 was $-11.5 Mil. It means NeoGenomics's Accounts Receivable increased by $11.5 Mil from Dec. 2022 to Dec. 2023 .
NeoGenomics's Accounts Receivable for the quarter that ended in Mar. 2024 was $140.3 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. NeoGenomics's Days Sales Outstanding for the three months ended in Mar. 2024 was 81.93.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NeoGenomics's liquidation value for the three months ended in Mar. 2024 was $-216.7 Mil.
The historical data trend for NeoGenomics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -17.30 | -12.60 | -4.69 | -7.58 | -11.52 |
NeoGenomics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 0.87 | -6.58 | -7.22 | 1.41 | -9.05 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics (NAS:NEO) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
NeoGenomics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 140.279 | / | 156.24 | * | 91 |
= | 81.93 |
2. In Ben Graham's calculation of liquidation value, NeoGenomics's accounts receivable are only considered to be worth 75% of book value:
NeoGenomics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 384.83 | - | 716.929 | + | 0.75 * 140.279 | + | 0.5 * 20.32 |
= | -216.7 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of NeoGenomics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Alicia C Olivo | officer: General Counsel | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
Anthony P. Zook | director | C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041 |
Elizabeth Floegel | director | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
Neil Gunn | director | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
Greg D Aunan | officer: Chief Accounting Officer | HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038 |
Jeffrey Scott Sherman | officer: Chief Financial Officer | 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027 |
Melody Harris | officer: President, Enterprise Ops | 4801 WEST BYRON PLACE, DENVER CO 80211 |
Warren Stone | officer: President, Clinical Services | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
David Brian Perez | director | 12100 6TH AVENUE, LAKEWOOD CO 80228 |
Christopher M Smith | officer: Chief Executive Officer | 125 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Shashikant Kulkarni | officer: President of Lab Operations | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
Vishal Sikri | officer: President and CCO, Inivata | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
David Sholehvar | officer: President, Clinical Services | 9490 NEOGENOMICS WAY, FORT MYERS FL 33912 |
William Bonello | officer: VP, Investor Relations | 12780 WESTLINKS DRIVE, FORT MYERS FL 33913 |
Kathryn B Mckenzie | officer: Principal Accounting Officer | 12780 WESTLINKS DRIVE, FORT MYERS FL 33913 |
From GuruFocus
By GuruFocus Research • 11-14-2023
By ACCESSWIRE ACCESSWIRE • 06-16-2023
By ACCESSWIRE ACCESSWIRE • 06-01-2023
By ACCESSWIRE • 08-08-2023
By ACCESSWIRE ACCESSWIRE • 05-03-2023
By ACCESSWIRE • 10-24-2023
By GuruFocus Research • 11-06-2023
By PRNewswire • 01-06-2024
By ACCESSWIRE • 07-27-2023
By Business Wire Business Wire • 03-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.